miR ‐194 suppresses high glucose‐induced non‐small cell lung cancer cell progression by targeting NFAT5

ConclusionOur findings provide new insight into the mechanism of NSCLC progression. Therapeutically, miR ‐194 may serve as a potential target for the treatment of lung cancer patients with DM.

Source: Thoracic Cancer - March 20, 2019 Category: Cancer & Oncology Authors: Xuying Meng, Zhenjin Li, Saijun Zhou, Shumin Xiao, Pei Yu Tags: ORIGINAL ARTICLE Source Type: research